Paradis, Pierre Emmanuel <br/><br/>
Economic impact of delays in listing decisions by provincial drug plans after a positive Common Drug Review recommendation: the case of a smoking-cessation treatment.  [electronic resource] 

 -  Healthcare quarterly (Toronto, Ont.)  2012 
 - 52-60 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1929-6347 
<br/><br/><label>Standard No.: </label>10.12927/hcq.2012.22912  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Age Factors<br/>Aged<br/>Benzazepines--economics<br/>Cost-Benefit Analysis<br/>Drug Costs--statistics & numerical data<br/>Female<br/>Humans<br/>Insurance, Health, Reimbursement--economics<br/>Insurance, Pharmaceutical Services--economics<br/>Male<br/>Middle Aged<br/>Quinoxalines--economics<br/>Saskatchewan--epidemiology<br/>Sex Factors<br/>Smoking--drug therapy<br/>Smoking Cessation--economics<br/>Time Factors<br/>Tobacco Use Cessation Devices--economics<br/>Varenicline<br/>Young Adult